A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis

Brief description of study

The purpose of this study is to see if the study drug Barzolvolimab (CDX-0159) is safe and effective at treating Active Eosinophilic Esophagitis (EoE). The total study duration for enrolled patients will be approximately 50 weeks (~11 months).


Clinical Study Identifier: s23-00387
Principal Investigator: Rita M. Knotts.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.